Dihydrophaseic acid | CAS:41756-77-8 | Manufacturer ChemFaces

Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Food Res Int.2018, 106:909-919

Drug Invention Today2019, 12(6):1303-1306

J Formos Med Assoc.2020, S0929-6646(20)30425-3

Natural Product Sciences2024, 30(4):254-261.

Pharmaceuticals (Basel).2021, 14(7):633.

Int J Mol Sci.2020, 21(24):9369.

NanoBioScience2024, v13:3:115.

BMC Plant Biol.2020, 20(1):214.

J Korean Soc Food Sci Nutr2023, 52(12):1248-1255

Cell Death Dis.2019, 10(12):882

Osteoporosis and Sarcopenia 2015,1(2):137-8.

Antiosteoporotic Activity of Dihydrophaseic Acid 3′-O-b-D-Glucopyranoside Derivatives from Lycii Radicis Cortex.[Reference: WebLink]

Our previous study demonstrated that ethanol extract of Lycii Radicis Cortex (LRC) prevented the ovariectomized-induced bone mineral density loss in mice via promoting the differentiation of osteoblast linage cells. A single compound, D3G, was isolated from the LRC extract as a candidate component enhancing bone formation. The aim of this study was to investigate the antiosteoporotic effects of Dihydrophaseic acid 3ʹ-O-b-D-glucopyranoside (D3G).
METHODS AND RESULTS:
The highest alkaline phosphatase activity was observed with 5 μg/ml of D3G in both cell lines: C3H10T1/2 and MC3T3-E1. The D3G treatment for 21 days increased the mineralized nodule formation in the MC3T3-E1 cell line. The expression of osteoblastic markers, Alpl, Runx2, and Bglap, was significantly increased in the D3G-treated cells compared to the non-treated control cells. The D3G treatment did not influence osteoclast differentiation in primary-cultured monocytes of mouse bone marrow. In coculture of monocytes and MC3T3-E1 cells, however, D3G induced both osteoblast and osteoclast differentiation.
CONCLUSIONS:
This study demonstrated that D3G increased the proliferation and differentiation of osteoblast cells and enhanced bone formation. These results suggest that D3G may be a good candidate for the treatment of osteoporosis

Plant Physiol. 1981 Jul;68(1):93-5.

Identification of a dihydrophaseic Acid aldopyranoside from soybean tissue.[Pubmed: 16661896 ]

METHODS AND RESULTS:
A previously unidentified abscisic acid metabolite has been isolated and characterized. (+/-)-[2-(14)C]Abscisic acid was incubated in intact soybean leaves and pods; the radiolabeled metabolite was purified by high performance liquid chromatography with on-line scintillation spectrometry detection. Gas chromatography-mass spectrometry was used to obtain spectra of the acetylated and methyl esterified derivatives.
CONCLUSIONS:
The data were consistent with a proposed Dihydrophaseic acid-aldopyranoside identity. Conjugation through the 4'-hydroxyl of Dihydrophaseic acid is suggested.

Product Name	Dihydrophaseic acid
CAS No.:	41756-77-8
Catalog No.:	CFN98657
Molecular Formula:	C₁₅H₂₂O₅
Molecular Weight:	282.3 g/mol
Purity:	>=98%
Type of Compound:	Sesquiterpenoids
Physical Desc.:	Powder
Source:	The herbs of Echinocystis macrocarpa
Solvent:	Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: